Influence of apo E phenotype on postprandial triglyceride and glucose responses in subjects with and without coronary heart disease

Atherosclerosis

Volumn 130, Issue 1-2, 1997, Pages 161-170

  Dart, Anthony ^a   Sherrard, Bridget ^a   Simpson, Harrison ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

apolipoprotein E; coronary heart disease; glucose; postprandial; triglyceride

Indexed keywords

APOLIPOPROTEIN E; GLUCOSE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; ALLELES; APOLIPOPROTEINS E; BLOOD GLUCOSE; BODY MASS INDEX; CORONARY DISEASE; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 0030975243     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)06062-5     Document Type: Article

References (54)

1. Nestel PJ. Is serum triglyceride an independent predictor of coronary heart disease? Pract Cardiol 1987;13:96.
2. Austin MA. Plasma triglyceride as a risk factor for coronary heart disease: the epidemiologic evidence and beyond. Am J Epidemiol 1989;129:249.
3. Hulley SB, Rosenman RH, Bawol RD, Brand RJ. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N Engl J Med 1980;302:1383.
4. Criqui MH, Heiss MPHG, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, Kritchevsky S, Jacobs DR, O'Grady HK, Davis CE. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993;328:1220.
5. Salonen JT, Puska P. Relation of serum cholesterol and triglycerides to the risk of acute myocardial infarction, cerebral stroke and death in eastern Finnish male population. Int J Epidemiol 1983;12:26.
6. Pocock SJ, Shaper AG, Phillips AN. Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischemic heart disease. Br Med J 1989;299:998.
7. Cambien F, Jacqueson A, Richard JL, Warnet JM, Ducimetiere P, Claude JR. Is the level of serum triglyceride a significant predictor of coronary death in 'normocholesterolemic' subjects? A Paris prospective study. Am J Epidemiol 1986;124:624.
8. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986;112:432.
9. West, KM, Ahuja MMS, Bennet PH, Czyzyk A, De Acosta OM, Fuller JH, Grab B, Grabauskas V, Jarrett RJ, Kosaka K, Keen H, Krolewski AS, Miki E, Schliack V, Teuscher A, Watkins PJ, Stober, J.A. The role of circulating glucose and triglyceride concentrations and their interactions with other 'risk factors' as determinants of arterial disease in nine diabetic populations from the WHO multinational study. Diabetes Care 1983;6:361.
10. Fontbonne A, Eschwege E, Cambien F, Richard JL, Ducimetiere P, Thibult N, Warnet JM, Claude JR, Rosselin GE. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris prospective study. Diabetologia 1989;32:300.
11. Carlson LA, Böttiger LE. Risk factors for ischemic heart disease in men and women: results of a 19-year old follow-up of the Stockholm prospective study. Acta Med Scand 1985;218:207.
12. Lapidus L, Bengtsson C, Lindquist O, Sigurdsson JA, Rybo E. Triglycerides - main lipid risk factor for cardiovascular disease in women? Acta Med Scand 1985;217:481.
13. Bouchier IAD, Bronte-Stewart B. Alimentary lipemia and ishcaemic heart disease. Lancet 1961;7173:363.
14. Denborough MA. Alimentary lipemia in ischemic heart disease. Clin Sci 1963;25:115.
15. Patsch JR, Miesenböck G, Hopferwieser T, Mühlberger V, Knapp E, Dünn JK, Gotto AM, Patsch W. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992;12:1336.
16. Karpe F, Steiner G, Olivecrona T, Carlson LA, Hamsten A. Metabolism of triglyceride-rich lipoproteins during alimentary lipemia. J Clin Invest 1993;91:748.
17. Simpson HS, Williamson CM, Olivecrona T, Pringle S, Maclean J, Lorimer AR, Bonnefous F, Bogaievsky Y, Packard CJ, Shepherd J. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis 1990;85:193.
18. Groot PHE, van Stiphout WAHJ, Krauss XH, Jansen A., van Tol A, van Ramshorst E, Chip-on S, Hofman A, Cresswell SR, Havekes L. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 1992:11:653.
19. Ginsberg HN, Jones J, Blaner WS, Thomas A, Karmally W, Fields L, Blood D, Begg MD. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler Thromb Vase Biol 1995;15:1829.
20. Huff MW, Evans AJ, Sawyez CG, Wolfe BM, Nestel PJ. Cholesterol accumulation in J774 macrophages induced by triglyceride-rich lipoproteins. Comparison of very low density lipoprotein from subjects with type III, IV and V hyperlipoproteinemias. Arterioscler Thromb 1991;11;221.
21. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82;495.
22. Goldstein JL, Ho YK, Brown MS, Innerarity TL, Mahley, RW. Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesteremic canine β-VLDL. J Biol Chem 1980;255:1839.
23. Chung BH, Segrest JP, Smith K, Griffin FM, Brouillette CG. Lipolytic surface remnants of triglyceride-rich lipoproteins are cytotoxic to macrophages but not in the presence of high density lipoprotein. A possible mechanism of atherogenesis? J Clin Invest 1989;83:1363.
24. Tiret L, de Kniff P, Menzel HJ, Ehnholm C, Nicaud V, Havekes LM. Apo E polymorphism and predisposition to coronary heart disease in youths of different European populations. Arterioscler Thromb 1994;14:1617.
25. Luc G, Bard JM, Arveiler D, Evans A, Cambou JP, Bingham A, Amouyel P, Schaffer P, Ruidavets JB, Cambien F, Fruchart JC, Ducimetiere P. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM study. Arterioscler Thromb 1994;14:1412.
26. Kamboh MI, Evans RW, Aston CE. Genetic effect of apolipoprotein(a) and apolipoprotein E polymorphisms on plasma quantitative risk factors for coronary heart disease in American black women. Atherosclerosis 1995;117:73.
27. Small GW, Kazziotta JC, Collins MT, Baxter LR, Phelps ME, Mandelkern MA, Kaplan A, La Rue A, Adamson CF, Chang L, Guze BH, Corder EH, Saunders AM, Haines JL, Pericak-Vance MA, Roses AD. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. J Am Med Assoc 1995;273:942.
28. Harris J, Benedict F. A Biometric Study of Basal Metabolism in Man. Washington: Carnegie Institute, 1919;279:40.
29. Menzel HJ, Utermann G. Apolipoprotein E phenotyping from serum by Western blotting. Electrophoresis 1986;7:492.
30. Norusis MJ. Base Manual/Advanced Statistics, SPSS/PC+. Chicago: SPSS Inc., 1986-1988.
31. Kosunen O, Talasniemi S, Lehtovirta M, Heinonen O, Helisalmi S, Mannermaa A, Paljarvi L, Ryynanen M, Riekkinen PJ Sr, Soininen H. Relation of coronary atherosclerosis and apolipoprotein E genotypes in Alzheimer patients. Stroke 1995;26:743.
32. Stengard JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 1995;91:265.
33. Ferrieres J, Sing CF, Roy M, Davignon J, Lussier-Cacan S. Apolipoprotein E polymorphism and heterozygous familial hypercholesterolemia: sex-specific effects. Arterioscler Thromb 1994;14:1553.
34. Boerwinkle E, Brown S, Sharrett AR, Heiss G, Patsch, W. Apolipoprotein E polymorphism influences postprandial retinyl palmitate but not triglyceride concentrations. Am J Hum Genet 1994;54:341.
35. Bergeron N, Havel RJ. Prolonged postprandial responses of lipids and apolipoproteins in triglyceride-rich lipoproteins of individuals expressing an apolipoprotein epsilon 4 allele. J Clin Invest 1996;97:65.
36. Brown AJ, Roberts DCK. The effect of fasting triacylglyceride concentration and apolipoprotein E polymorphism on postprandial lipemia. Arterioscler Thromb 1991;11:1737.
37. Reznik Y, Pousse P, Herrou M, Morello R, Mahoudeau J, Drosdowsky MA, Fradin S. Postprandial lipoprotein metabolism in normotriglyceridemic non-insulin-dependent diabetic patients: influence of apolipoprotein E polymorphism. Metabolism 1996;45:63.
38. Nikkila M, Solakivi T, Lehtimaki T, Koivula T, Laippala P, Astrom B. Postprandial plasma lipoprotein changes in relation to apolipoprotein E phenotypes and low density lipoprotein size in men with and without coronary artery disease. Atherosclerosis 1994;106:149.
39. Greg RE, Zech LA, Schaefer EJ, Stark D, Wilson D, Brewer HB Jr. Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest 1986;78:815.
40. Miller GJ. High density lipoproteins and atherosclerosis. Annu Rev Med 1980;31:97.
41. Bergstrom RW, Leonetti DL, Newell-Morris LL, Shuman WP, Wahl PW, Fujimoto WY. Association of plasma triglyceride and C-peptide with coronary heart disease in Japanese-American men with a high prevalence of glucose intolerance. Diabetologia 1990;33:489.
42. Rönnemaa T, Laakso M, Pyörälä K, Kallio V, Puukka P. High fasting plasma insulin is an indicator of coronary heart disease in non-insulin-dependent diabetic patients and nondiabetic patients. Arterioscler Thromb 1991;11:80.
43. Fujiwara R, Kutsumi Y, Hayashi T, Kim SS, Misawa T, Tada H, Nishio H, Toyota K, Tamai T, Nakai T, Miyabo S. Metabolic risk factors in the normolidemic male patients with angiographically defined coronary artery disease. Jpn Circ J 1990;54:493.
44. Fontbonne A, Charles MA, Thibult N, Richard JL, Claude JR, Warnet JM, Rosselin GE, Eschwege E. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris prospective study, 15-year follow-up. Diabetelogia 1991;34:356.
45. Fontbonne AM, Eschwege EM. Insulin and cardiovascular disease. Paris prospective study. Diabetes Care 1991;14:461.
46. Pyörälä K. Hyperinsulinaemia as a predictor of athersclerotic vascular disease: epidemiological evidence. Diabetes Metab 1991;17:87.
47. Detry JM, Kapita BM, Cosyns J, Sottiaux B, Brasseur LA, Rousseau MF. Diagnostic value of history and maximal exercise electrocardiography in men and women suspected of coronary heart disease. Circulation 1977;56:756.
48. Kemp HG, Vokonas PS, Cohn PF, Gorlin R. The anginal syndrome associated with normal coronary arteriograms. Am J Med 1973;54:735.
49. Opherk D, Zebe H, Weihe E, Mall G, Dürr C, Gravert B, Mehmel HC, Schwarz F, Kübler W. Reduced coronary dilatory capacity and ultrastructural changes of the myocardium in patients with angina pectoris but normal coronary arteriograms. Circulation 1981;63:817.
50. Heart and Stroke Facts Report. Canberra: National Heart Foundation of Australia, 1995.
51. Weinberger MH. Antihypertensive therapy and lipids: evidence, mechanisms and implications. Arch Intern Med 1985;14:1102.
52. Giles TD. Antihypertensive therapy and cardiovascular risk. Are all antihypertensives equal? Hypertension 1992;19(Suppl I):124.
53. Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease, a meta-analysis. Arterioscler Thromb Vase Biol 1996;16:1250.
54. Katzel LI, Fleg JL, Paidi M, Ragoobarsingh N, Goldberg AP. Apo E4 polymorphism increases the risk for exercise-induced silent myocardial ischemia in older men. Arterioscler Thromb 1993;13:1495.